
The PDUFA date has been set for May 22, 2023.

The PDUFA date has been set for May 22, 2023.

Women on Medicaid with opioid use disorder (OUD) who use medications for opioid use disorder (MOUD) are more likely to use contraception and to undergo female sterilization than peers not prescribed MOUD.

Patients are finding relief in alternative therapies for this chronic skin disease.

Take a look back at our most popular pain management coverage for 2022.

Biosimilar medications stand to significantly increase cost savings for patients.

New pathways of care are needed to improve health care spending.

Haylea Hannah, MSPH, PhD, discusses her research on the barriers to medications for opioid use disorder that people who are incarcerated can face and what pharmacists can do to address the barriers.

Investigators set out to evaluate how medication access for certain rheumatic conditions has changed since June 2022.

Results from a randomized controlled trial study suggest dextromethorphan may even worsen patient pain experience.

We may be one step closer to nonprescription naloxone.

As the main course of treatment for cancer-related pain, the use of opioids comes with a number of issues for both patients and prescribers.

Cannabinoids lack the habit-forming mechanism of action found in methadone and buprenorphine, unlocking new potential for the drug.

Positive effects emerge when patients get medical care, avoid deadly fentanyl-laced street drugs.

Study finds growth in three years after CDC guideline for primary care clinicians.

Are prescription cap laws for opioids effective for children and teenagers?

Used to treat a variety of concerns and found in many medicine cabinets, new research indicates that nonsteroidal anti-inflammatory drugs may pose a risk to patients with type 2 diabetes.

A variety of nonprescription treatments, supplements, and patches can alleviate pain for children and adolescents.

Buprenorphine can only be prescribed by pharmacists with waivers, limiting access to this necessary treatment for communities.

A pharmacist reflects on how prescribing behaviors have changed over the years and the potential for stigma linked to providing buprenorphine to patients who need it.

Fentanyl, COVID-19 pandemic likely factors in 30% increase from previous year.

Study finds growth in three years after CDC guideline for primary care clinicians.

Patients with central sensitization struggle more with pain and quitting opioids

Ruling comes in cases with prison sentences for convictions over prescription drugs.

Understanding headaches and their various treatment options can help pharmacists counsel patients at the counter.

Patients may use drugs for reasons or time frame other than intended by prescriber, according to study.